Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 7.13Hikal Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, indicating a solid foundation and effective management in these areas. However, liquidity and efficiency are areas of concern, suggesting potential challenges in meeting short-term obligations and optimizing asset utilization. The company's coverage ratios are reasonably good, reflecting its ability to meet its interest and dividend commitments. While the financial ratios are weak, the other strong areas provide a somewhat balanced view. Overall, Hikal Ltd appears to be a company with considerable strengths in long-term sustainability and earnings potential, but it needs to address its short-term financial management to ensure continued success.
Health Score : 7.13Hikal Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, indicating a solid foundation and effective management in these areas. However, liquidity and efficiency are areas of concern, suggesting potential challenges in meeting short-term obligations and optimizing asset utilization. The company's coverage ratios are reasonably good, reflecting its ability to meet its interest and dividend commitments. While the financial ratios are weak, the other strong areas provide a somewhat balanced view. Overall, Hikal Ltd appears to be a company with considerable strengths in long-term sustainability and earnings potential, but it needs to address its short-term financial management to ensure continued success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-50.26
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
-50.14
P/B RATIO
2.04
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
1.39
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
18.42
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹198.54 as on Sep 1, 2026.
Growth Score : 10.00The company exhibits strong growth across all key metrics, including revenue, operating profit, EPS, assets, and net income. The company is expanding its operations and increasing its profitability. This suggests that the company is well-positioned for future success and has a competitive advantage in the market.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 12.97 | 4.12 | -11.76 | 4.2 | -7.9 |
| Operating Profit Growth Rate | 5.57 | -24.34 | 3.49 | 22.85 | -32.93 |
| Earnings Per Share (EPS) Growth | 20.56 | -51.15 | -11.32 | 30.5 | -153.8 |
| Asset Growth Rate | 15.68 | 7.77 | 4.28 | 1.69 | |
| Net Income Growth Rate | 20.3 | -51.25 | -10.26 | 30 | -153.85 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 6 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 7 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 8 | Morepen Laboratories Ltd | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 9 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 10 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 11 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 12 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 13 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 14 | Indoco Remedies Ltd | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 15 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 16 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 17 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 19 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Hikal Ltd is an integrated Indian pharmaceutical and crop protection company. It specializes in contract manufacturing and development (CDMO) services, supplying active pharmaceutical ingredients (APIs), intermediates, and crop protection chemicals globally. The company focuses on research and development to offer innovative solutions across its diverse product portfolio.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Hikal Ltd's P/E ratio (TTM) is -50.26, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Hikal Ltd's P/B ratio is 2.04, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Hikal Ltd's P/S ratio is 1.39, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Hikal Ltd's PEG ratio is 1.25.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Hikal Ltd's EV/EBITDA ratio is 18.42.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Hikal Ltd's ROE is 7.21%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Hikal Ltd's ROA is 12.97%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Hikal Ltd's ROCE is 4%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Hikal Ltd's operating margin is 12.84%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Hikal Ltd's net margin is -2.86%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Hikal Ltd's current ratio is 1.15.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Hikal Ltd's debt-to-equity ratio is 0.30.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Hikal Ltd's interest coverage ratio is -0.26.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Hikal Ltd's DPS is ₹0.59.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Hikal Ltd's EPS is -153.80.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹198.54. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1988 (as Hikal Chemical Industries Limited)
Headquarters: Mumbai, Maharashtra
Core Offerings: Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Crop Protection Chemicals, CDMO Services
Stock Listing: NSE (HIKAL), BSE (524735)
Promoter: Hiremath Family
1988: Incorporated as Hikal Chemical Industries Limited. 1991: Started commercial production of speciality chemicals at Taloja plant. 1994: Established a dedicated R&D facility and completed IPO. 1999: Acquired manufacturing facility in Jigani, Bangalore, for pharma intermediates. 2005: Name changed to Hikal Limited to reflect broader business scope. 2007: Acquired manufacturing facility in Panoli, Gujarat. 2011: Expanded CDMO services in pharmaceuticals. Present: Continues to expand its global footprint in pharmaceuticals and crop protection.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceuticals | 72% | 16% margin |
| Crop Protection | 28% | 18% margin |
Pharmaceuticals: Engages in contract development and manufacturing (CDMO) services for global pharmaceutical companies, along with manufacturing active pharmaceutical ingredients (APIs) and intermediates. Focuses on therapeutic areas such as anti-diabetic, anti-depressant, and anti-psychotic.
Crop Protection: Manufactures and supplies a wide range of crop protection chemicals, including fungicides, insecticides, and herbicides, both for global innovators under contract manufacturing and for its own product portfolio. Utilizes its multi-purpose facilities for various chemical processes.
Jai Hiremath - Chairman and Managing Director. A visionary entrepreneur with over three decades of experience in the chemical and pharmaceutical industries, he founded Hikal and has been instrumental in its growth and strategic direction.
Hikal International Inc., USA
Hikal Real Estate Private Limited, India
Acoris Research Limited, India
Hikal LLC, USA
No major recent corporate actions on record.
The Hikal Ltd share price today is ₹198.54 on NSE (HIKAL), as of 26 Sept 2026.
As of 25 Sept 2026, Hikal Ltd share price is ₹198.54, with previous close ₹198.54. Today's range is ₹198.54 to ₹198.54. The 52-week range is ₹146.25 to ₹261.
As of today, Hikal Ltd's market cap is ₹2,374.54 crore (Small Cap).
Hikal Ltd's current P/E ratio is -50.26, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.
Hikal Ltd's current P/B ratio is 2.04.
Hikal Ltd's current dividend yield is 0.30%. Last dividend of ₹0.80 per share was declared on 24-May-2024.
Hikal Ltd's EPS (TTM) is ₹-153.80.
Hikal Ltd is an integrated Indian pharmaceutical and crop protection company. It specializes in contract manufacturing and development (CDMO) services, supplying active pharmaceutical ingredients (APIs), intermediates, and crop protection chemicals globally. The company focuses on research and development to offer innovative solutions across its diverse product portfolio.
Hikal Ltd is promoted by Hiremath Family, holding 68.85% as of 25 Sept 2026.
Hikal Ltd is listed on NSE (HIKAL) and BSE (524735). Its next quarterly results are expected on July/August 2024.
Fixed Asset Turnover Ratio
